ELDN

Eledon Pharmaceuticals Stock Analysis

AI Rating

Neutral
  • Quality0/10
  • Growth 7/10
  • Value 5/10
Eledon Pharmaceuticals sales and earnings growth
ELDN Growth
Good
  • Revenue Y/Y 0.00%
  • EPS Y/Y -4.05%
  • FCF Y/Y -26.20%
Eledon Pharmaceuticals gross and profit margin trends
ELDN Profitability
Low
  • Gross margin 0.00%
  • EPS margin 0.00%
  • ROIC 5Y -117.61%
Eledon Pharmaceuticals net debt vs free cash flow
ELDN Risk
Great
  • Debt / Equity 0.0
  • Debt / FCF 0.0
  • Interest coverage NA

Eledon Pharmaceuticals stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks